AMEDS in Poland has been studying which patients receive the most benefit from venoplasty for CCSVI.    Here is the link to their study in pdf form:

http://ameds.co/ftp/who_benefits_most_from_ccsvi_treatment_by_ameds_centrum.pdf

A total of 47 patients suffering from Multiple Sclerosis (MS) with confirmed diagnosis of Chronic Cerebro-Spinal Venous Insufficiency (CCSVI) who underwent endovascular treatment at AMEDS Centrum were included in this study. According to the change in EDSS (Extended Disability Status Scale) patients were divided into two groups: patients with improvement and patients without improvement. 

Dissimilarities in distribution by age and gender were observed between two groups of patients. Majority of patients with improvement were female (69%) compared to almost equal distribution (female 53%) in group without improvement. Improvement group was dominated by Relapsing-Remitting (RR) type of MS (77%), while among patients without improvement distribution was more even (RR – 35%; Secondary Progressive (SP) –30%; Primary Progressive (PP) – 35%). 

Improvement rates varied directly with age of patients (75% vs. 22% of patients below 30 years and of those over 50 respectively) and disease duration (63% vs. 21% of patients with a history of disease lasting for less than 5 years and of those with disease lasting longer than 15 years respectively). 

Average disease duration is found to be significantly shorter in patients experiencing improvement compared to group with no improvement (8,9 years vs. 15,8 years). It is also worth noting that positive change in patients condition correlated with baseline EDSS. 

Our results of the study suggest that endovascular treatment may be more beneficial in some groups of patients. 

The improvement group was dominated by females (69% vs. 31% – males). Three out of four patients in the group with improvement were suffering from Relapsing-Remitting type of MS. However, it should be noted that CCSVI treatment is associated with positive results in people suffering from other types of MS as well. 

Our study also showed that young patients (age below 30) with short disease duration would probably be most advantageous. 

Characteristics of patients who have had positive results from CCSVI treatment indicate that most beneficial groups are: 

Females 

Relapsing-Remitting type of MS 

At young age 

With short disease duration 

With lower baseline EDSS. 

Note--as a male above 40, my husband doesn't fit the positive result profile.  He was recently diagnosed and low EDSS, however.  For those who has seen benefit from treatment, do you fit this profile?  

Let us know--

Joan